MAPT and amyloidosis: Furthermore, with or without other measures, abnormal plasma biomarker levels exhibited high predictive accuracy for future AD-related endophenotypes, including worsening cognition, brain atrophy, and tau or amyloid burden evaluated by PET, in non-demented participants19,29–32.